Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats

Journal of Hypertension

Volumn 27, Issue 4, 2009, Pages 800-805

  Zhu, Aoshuang ^a   Yoneda, Takashi ^a   Demura, Masashi ^a   Karashima, Shigehiro ^a   Usukura, Mikiya ^a   Yamagishi, Masakazu ^a   Takeda, Yoshiyu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

(pro)renin receptor; Aldosterone antagonist; Angiotensin II type 1 receptor; Angiotensinogen; Kidney; Sodium

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PRORENIN RECEPTOR;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY INJURY; KIDNEY MASS; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCORING SYSTEM; URINARY EXCRETION;

EID: 67649641510     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328325d861     Document Type: Article

References (28)

1. Nguyen G, Contrepas A. The (pro)renin receptors. J Mol Med 2008; 86:643-646.
2. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003; 41:592-597.
3. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, et al. Effects of AT1 receptor blockade on renal injury and mitogenactivated protein activity in Dahl salt-sensitive rats. Kidney Int 2004; 65:972-981.
4. Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens 2006; 24 (suppl 1):S101-S106.
5. Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27:781-789.
6. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
7. Klar J, Vitzthum H, Kurtz A. Aldosterone enhances renin gene expression in juxtaglomerular cells. Am J Physiol Renal Physiol 2004; 286:F349-F355.
8. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104:137-139.
9. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004; 143:41-51.
10. Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007; 20:1119-1124.
11. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000; 36:495-580.
12. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995; 26 (part 1):932-936.
13. Miyamori I, Matsubara T, Takeda Y, Koshida H, Soma R, Takeda R. Angiotensin II generation in mesenteric arteries in rats: effects of nephrectomy, deoxycorticosterone and dexamethasone. Endocrinol Jpn 1990; 37:9-17.
14. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47:1084-1093.
15. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Yagi S. Antihypertensive effect of interleulin-2 in salt-sensitive Dahl rats. Hypertension 1994; 23:68-73.
16. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47:894-900.
17. Kobori H, Nangaku M, Nabar LG, Nishiyama A. The intrarenal reninangiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251-287.
18. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Srar JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
19. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangeal cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113.
20. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide connresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114:1128-1135.
21. Sun Z, Cade R, Zhang Z, Alouidor J, Van H. Angiotensinogen gene knockout delays and attenuates cold-induced hypertension. Hypertension 2003; 41:322-327.
22. Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int 2006; 69:1016-1023.
23. Yoo T-H, Li J-J, Kim JJ, Jung DS, Kwak SJ, Ryu DR. Activation of the reninangiotensin system within podocytes in diabetes. Kidney Int 2007; 71:1019-1027.
24. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J kidney Dis 2001; 37:677-688.
25. Endemann DH, Touyz RM, Iglarz M, Savoia CE, Schiffrin L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in strokeprone spontaneously hypertensive rats. Hypertension 2004; 43:1252-1257.
26. Seccia TM, Maniero C, Belloni AS, Guidolin D, Pothen P, Pessina AC, Rossi GP. Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis. J Hypertens 2008; 26:2022-2029.
27. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16:781-788.
28. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20:1329-1333.